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 ABSTRACT  
 Objectives  To study the role of interleukin 22 (IL-22) in 
rheumatoid arthritis (RA). 
 Methods  IL-22 serum levels were measured in patients 
with early, treatment-naive RA (n=49) and in 45 
age- and sex-matched healthy individuals as controls. 
Patients were assessed clinically and radiographically at 
baseline and followed up for 2 years. Correlations of IL-22 
serum levels were sought with parameters of disease 
activity, serological markers, demographic factors and 
the incidence of erosions. IL-22 production by peripheral 
blood T cells was investigated by intracellular fl ow 
cytometry. 
 Results  24 of 49 patients with RA demonstrated 
elevated IL-22 levels compared with the range of healthy 
controls. At baseline, a high percentage of these patients 
(8/24, 33%) demonstrated bone erosions, whereas only 
one patient (4%) from the group with normal IL-22 had 
erosions. During the 2 years of follow-up, six additional 
patients with increased IL-22 at baseline developed 
erosions. In contrast, none of the patients in whom 
IL-22 levels were normal developed erosions despite 
similar treatment regimens. Multivariate regression 
analysis accounting for other parameters predictive for 
erosions, such as the presence of rheumatoid factor or 
anti-cyclic citrullinated peptide antibodies and disease 
activity, showed that elevated IL-22 baseline levels were 
independently and signifi cantly associated with erosive 
RA. Cellular analysis demonstrated enhanced expression 
of IL-22 from CD4 T cells in RA. 
 Conclusion  IL-22 is elevated in the serum of half 
of the patients with RA. Elevated serum IL-22 allows 
discrimination between patients with different 
radiographic progression and indicates a possible 
involvement of IL-22 in the pathophysiology of RA. 
 INTRODUCTION 
 Rheumatoid arthritis (RA) is an autoimmune dis-
ease characterised by persistent synovitis and 
the development of erosive joint destruction. 
Imbalance in the expression of certain cytokines 
promoting the disease is a key feature of RA. 1 
Interleukin 22 (IL-22) was recently identifi ed as a 
cytokine potentially contributing to joint pathol-
ogy. IL-22-defi cient mice develop decreased pan-
nus formation and bone destruction in the course 
of collagen-induced arthritis as compared with 
their wild-type littermates. 2 The receptor for IL-22, 
IL-22R1, is expressed in both the lining and the 
sublining layers of RA synovial tissues. 3 Further, 
IL-22 was found to be elevated in patients with 
early RA, particularly in the synovium. 4 In vitro, 
IL-22 increases the proliferation of human RA syn-
ovial fi broblasts and the production of monocyte 
chemotactic protein 1, a critical chemokine for the 
recruitment of macrophages into the joints during 
rheumatoid infl ammation. 3  5 IL-22 has also been 
shown to promote osteoclastogenesis from mac-
rophages, further contributing to bone destruction 
in the arthritic process. 2 
 IL-22 is primarily produced by activated T cells 
and natural killer cells. Among T cells, the high-
est expression of IL-22 has been detected in CD4 
memory cells. 6  7 Th17 cells have been consistently 
shown to co-express IL-22, which led to the sug-
gestion that IL-22 is a Th17 cytokine. 8 However, 
in humans signifi cant IL-22 production was also 
demonstrated by so called ‘Th22’ cells—a recently 
described CD4 T cell population that is negative for 
IL-17A and interferon γ (IFNγ)—and also by Th1 
cells. 9  10 In addition to these subsets, cells with a 
mixed phenotype capable of producing all of these 
cytokines, IL-22, IL-17 and IFNγ, can be detected in 
human blood. 9  11 
 In this study, we studied the association of IL-22 
expression with clinical parameters and the radio-
logical outcome in a cohort of treatment-naive 
patients with early RA. About half (49%) of the 
patients showed elevated levels of serum IL-22 at 
baseline. Accordingly, patients could be subdivided 
into two groups: one with IL-22 levels within the 
normal range (‘IL-22 normal’ group, 25/49 patients) 
and another with markedly elevated IL-22 serum 
levels (‘IL-22 high’ group, 24/49 patients). Whereas 
no correlation was detected between IL-22 serum 
level and measures of clinical disease activity or 
specifi c clinical feature, the association between 
the presence of elevated IL-22 in the serum at base-
line and the development of erosions was strik-
ing and highly signifi cant after 1 and 2 years. The 
data suggest a pathophysiological role for IL-22 in 
bone erosion. As a potential source of the elevated 
IL-22 serum level, increased frequencies of IL-22-
producing CD4 T cells were detected in the patients 
with RA compared with controls. 
 PATIENTS AND METHODS 
 Study population 
 Peripheral blood (PB) was obtained at the time 
of the fi rst clinical evaluation from 49 patients 
( table 1 ) who fulfi lled the American College of 
Rheumatology revised criteria for the diagnosis of 
RA. 12 The patients had active disease as defi ned by a 
Disease Activity Score in 28 joints (DAS28) of ≥3.2. 
The patients had a mean RA duration of <5 months 
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since their initial clinical symptoms, and had never been treated 
with glucocorticoids or disease-modifying antirheumatic drugs 
(DMARDs). Demographic and clinical parameters such as age, 
gender, smoking, disease duration, use of non-steroidal anti-
infl ammatory drugs, tender joint count, swollen joint count, 
DAS28 values, erythrocyte sedimentation rate and levels of 
C-reactive protein, rheumatoid factor (RF) and anti-cyclic citrul-
linated peptide (anti-CCP) antibodies were collected at the time 
of blood sampling. Radiographs of hands and feet were obtained 
at initial contact, and after 1 and 2 years after disease onset. For 
two patients baseline but no follow-up data were available as 
they were lost during follow-up. An independent experienced 
radiologist blinded to the clinical data and the study questions 
evaluated the radiographs for the presence of erosions. 
 Treatment of all patients was started with methotrexate 
(15 mg/week) often initially combined with glucocorticoids. If 
insuffi cient to control disease activity, the methotrexate dose 
was escalated and/or patients received a second DMARD 
(eg, lefl unomide). In the case of conventional DMARD failure, 
biological agents, predominantly tumour necrosis factor (TNF) 
blocking agents were started (22.7% vs 23.8%, ‘IL-22 normal’ vs 
‘IL-22 high’ group). The treating doctors were blinded to base-
line IL-22 levels of the individual patient. For control, 45 age-
matched healthy individuals were analysed ( table 1 ). Written 
informed consent was provided by all patients and healthy 
donors. The study was approved by the ethics committee of the 
University of Munich. 
 Cell purifi cation 
 Mononuclear cells from PB were isolated by Ficoll density-
gradient centrifugation (Lymphofl ot; Biotest AG, Dreieich, 
Germany). Untouched memory CD4 CD45RO T cells were 
isolated by negative selection using magnetic beads (Miltenyi 
Biotech, Bergisch Gladbach, Germany). Purity was routinely 
controlled by fl ow cytometry. Purifi ed T cells were more than 
95% positive for CD3/CD4 and CD45RO. 
 Cell culture 
 Cell cultures were performed in RPMI 1640 medium supple-
mented with penicillin G (50 U/ml), 50 μg/ml streptomycin, 2 mM 
L-glutamine (all from Gibco/Invitrogen, Carlsbad, California, 
USA), 10 IU/ml recombinant human IL-2 (Proleukin; Chiron, 
Emeryville, California, USA) and 10% normal human serum 
at 37°C in a humidifi ed atmosphere containing 5% CO 2 . Cells 
(0.5×10 6 cells/ml) were activated in 48-well plates under non-
priming conditions for 5 days by plate-bound anti-CD3 (1 μg/ml; 
OKT3; American Type Culture Collection, Manassas, Virginia, 
USA) and soluble anti-CD28 (1 μg/ml; 28.2; BD Bioscience, 
San Jose, California, USA), rested for 2 days and restimulated for 
5 h with 1 mM ionomycin (Calbiochem, San Diego, California, 
USA) and 20 ng/ml phorbol myristate acetate in the presence of 
2 μM monensin for intracellular cytokine detection (both from 
Sigma-Aldrich, St Louis, Missouri, USA). 
 Flow cytometry 
 For extracellular fl ow cytometry, cells were washed with 2% 
fetal calf serum in phosphate-buffered saline (FCS/PBS), stained 
with directly fl uorochrome-labelled monoclonal antibodies 
against different surface molecules as indicated, and analysed on 
a Cytomics FC500 fl ow cytometer with CXP software (Beckman 
Coulter, Fullerton, California, USA). The antibodies used were 
as follows: fl uorescein isothiocyanate (FITC)-labelled anti-CD3, 
phycoerythrin (PE)-labelled anti-CD4, FITC-labelled anti-CD27, 
PE-labelled anti-CD45RO (all from BD Biosciences). 
 For cytoplasmic cytokine staining, restimulated cells were 
fi xed in 4% paraformaldehyde (Merck, Darmstadt, Germany) 
and permeabilised with 0.1% saponin (Sigma-Aldrich) in PBS 
containing 2% FCS (Gibco/Invitrogen). The non-specifi c bind-
ing sites were blocked with 4% rat and mouse serum (both 
from Sigma-Aldrich). Afterwards, cells were incubated with 
FITC-labelled anti-IFNγ (BD Biosciences), PE-labelled anti-
IL-22 and allophycocyanin-labelled anti-IL-17 (both from R&D 
Systems Minneapolis, Minnesota, USA) for 30 min at 4°C. 
After washing with 0.1% saponin in 2% FCS/PBS, cells were 
resuspended in 2% FCS/PBS and analysed for cytoplasmic 
cytokines by three-colour fl ow cytometry. 
 ELISA 
 Levels of IL-22, IL-17 and TNF in the serum samples were assessed 
using ELISA kits according to the manufacturer’s instructions 
(R&D Systems eBioscience, San Diego, California USA, and 
Biolegend, San Diego, California, USA). Patients with RA were 
classifi ed as ‘IL-22 normal’ or ‘IL-22 high’ if IL-22 serum levels 
did not or did, respectively, exceed the upper limit of the normal 
range as defi ned by the mean±3 SDs of 45 healthy individuals. 
 Statistical analysis 
 Differences between different cohorts of patients were deter-
mined by Mann–Whitney test, Student t test, or Fisher’s exact 
test, where applicable. To account for confounding effects multi-
variate logistic regression analysis was performed. p Values <0.05 
were considered statistically signifi cant. The analyses were per-
formed using SPSS 19 (SPSS, Chicago, Illinois, USA) and Prism 
5.0 software (GraphPad Software, San Diego, California, USA). 
 RESULTS 
 IL-22 baseline levels in patients with RA are associated with 
radiological progression 
 To investigate the role of IL-22 in the systemic autoimmune dis-
ease RA, we fi rst determined IL-22 levels in the PB of a cohort 
of patients with RA with very early, active disease ( table 1 ). 
These patients had never been treated with glucocorticoids or 
 Table 1 Baseline clinical and demographic parameters of the study 
population * 
Parameters
 Healthy controls 
(n=45) 
 Patients with RA 
(n=49) 
Age (years) 51.6±7.6 53.1±12.8
Female/male (n) 32/13 37/12
Smoking habit (%) 36.4 53.1
Disease duration (months) NA † 4.0±3.4
NSAID use (%) NA 72.9
RF positive (%) ND ‡ 75.5
Anti-CCP positive (%) ND 69.4
DAS28 NA 4.6±1.3
TJC (n) NA 6.5±4.9
SJC (n) NA 5.8±4.7
CRP (mg/dl) ND 2.4±3.9
ESR (mm/h) ND 31.5±33.3
Interleukin 22 (pg/ml) 3.3±1.4 15.1±15.9
 * Data are shown as the mean±SD or absolute numbers. 
 † NA, not applicable. 
 ‡ ND, not determined. 
 anti-CCP, anti-cyclic citrullinated peptides; CRP, C-reactive protein; DAS28, Disease 
Activity Score in 28 joints; ESR, erythrocyte sedimentation rate; NSAIDs, non-steroidal 
anti-infl ammatory drugs; RA, rheumatoid arthritis; RF, rheumatoid factor; SJC, swollen 
joint count; TJC, tender joint count. 
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DMARDs to rule out possible infl uences of immunosuppressive 
drugs on cytokine expression. Serum IL-22 levels were higher in 
patients with RA than in healthy controls (p<0.0001,  table 1 and 
 fi gure 1 ). Based on the IL-22 serum level, two groups of patients 
were identifi ed within the RA cohort. A fi rst group with IL-22 
levels within the normal range was denoted as ‘normal IL-22’, 
and a second group with markedly elevated lL-22 serum levels 
was designated as ‘high IL-22’ ( table 2 ). The two groups did not 
differ signifi cantly for parameters of disease activity—for exam-
ple, DAS28, tender joint count, swollen joint count, C-reactive 
protein levels and erythrocyte sedimentation rate at baseline or 
during the follow-up ( table 2 and data not shown). Although 
the proportion of autoantibody-positive (RF, anti-CCP) patients 
and the proportion of smokers was greater in the ‘IL-22 high’ 
group than in the ‘IL-22 normal’ RA group, this difference was 
not statistically signifi cant. No correlation was detected, when 
serum levels of IL-17 and TNF were measured in order to assess 
whether other infl ammatory cytokines correlated with the IL-22 
serum level ( table 2 ). However, although no direct correlation 
between serum IL-22 and IL-17 was evident, IL-17 concentra-
tions were signifi cantly greater in the ‘IL-22 high’ than in the 
‘IL-22 normal’ group (p<0.05). 
The association of baseline IL-22 levels and radiographic pro-
gression as shown by the presence of erosions was assessed 
at baseline, and after 1 and 2 years of follow-up. To exclude 
confounding effects of other parameters associated with erosive 
disease we performed multivariate regression analysis correct-
ing for the presence of anti-CCP antibodies and RF, and disease 
activity at baseline ( table 3 ). Patients with high baseline IL-22 
serum levels more often manifested bone erosions than patients 
from the ‘IL-22 normal’ group already at the onset of the dis-
ease (8/24 (33%) vs 1/25 (4%), p=0.05) ( table 3 ). Five additional 
patients had developed bone erosions at 1 year, and a sixth 
patient at 2 years of follow-up. All those patients were from the 
‘IL-22 high’ group ( table 3 ). As a consequence, at 1 and 2 years, 
the association of elevated IL-22 baseline serum levels with bone 
erosions was pronounced and signifi cant (13/23 (57%) vs 1/24 
(4%), p<0.01, and 14/23 (61%) vs 1/24 (4%), p<0.005, respec-
tively) ( table 3 ). Importantly, extending the regression model for 
confounding effects of smoking, age, gender, disease duration, 
each alone or in combination, did not alter the signifi cant asso-
ciation of IL-22 baseline level with erosive disease. 
 Increased IL-22-producing CD4 T cells in RA 
 Next, we assessed the frequencies of different CD4 T cell popula-
tions producing IL-22 in patients with RA. Memory CD4 T cells 
were expanded for 5 days and analysed for intracellular cytokine 
production. CD4 T cells from four patients with RA contained sub-
stantially higher frequencies of IL-22-producing cells as compared 
with control cells ( fi gure 2A , B ). Three-colour analysis revealed that 
CD4 T cells from patients with RA contained signifi cantly higher 
frequencies of ‘pure’ IL-22 producers (‘Th22’ cells; IL-22+IL-17–
IFNγ–) ( fi gure 2B ). Moreover, in RA increased frequencies of IL-22-
producing cells were found within the Th17 (IL-22+IL-17+IFNγ–) 
and the Th1 (IL-22+IL-17–IFNγ+) cell populations ( fi gure 2B ). The 
triple-producing cells (IL-22+IL-17+IFNγ+) were also increased 
in patients with RA ( fi gure 2B ). Interestingly, whereas the IL-22-
producing fraction within the Th17 cells was of comparable size 
 Figure 1  (A) Serum IL-22 concentration of healthy controls (HC; 
n=45) and patients with RA (n=49). The shaded area denotes the 
normal range (mean±3 SDs) of healthy individuals. IL-22, interleukin 22; 
RA, rheumatoid arthritis. 
 Table 2  Clinical and serological parameters in patients with RA 
stratifi ed according to the IL-22 serum level at baseline * 
 
 ‘IL-22 normal’ 
(n=25) † 
 ‘IL-22 high’ 
(n=24) ‡  p Value § 
IL-22 (pg/ml) 4.3±1.4 26.2±16.1 <0.0001
Age (years) 54.7±11.1 51.3±13.8 NS
Female/male (n) 20/5 17/7 NS
Disease duration (months) 4.3±4.2 3.9±3.2 NS
NSAID use (%) 72.0 75.0 NS
Smoking habit (%) 44.0 62.5 NS
RF positive (%) 64.0 87.5 NS
Anti-CCP positive (%) 60.0 79.2 NS
DAS28 4.5±1.3 4.7±1.2 NS
TJC (n) 6.2±5.2 6.7±4.5 NS
SJC (n) 5.6±5.0 5.9±4.3 NS
CRP (mg/dl) 2.4±3.6 2.4±4.1 NS
ESR (mm/h) 31.8±33.0 31.3±33.7 NS
TNF (pg/ml) 0.2±1.0 0.5±1.9 NS
IL-17 (pg/ml) 2.8±3.9 8.7±13.9 <0.05
 * Data are shown as mean±SD or absolute numbers. 
 † Patients with RA characterised by a normal IL-22 serum level (<7.5 pg/ml). 
 ‡ Patients with RA characterised by a raised IL-22 serum level (>7.5 pg/ml). 
 § p Values were calculated between the ‘IL-22 normal’ and ‘IL-22 high’ group by 
Mann–Whitney test or where applicable by Fisher’s exact test. 
 anti-CCP, anti-cyclic citrullinated peptides; CRP, C-reactive protein; DAS28, Disease 
Activity Score in 28 joints; ESR, erythrocyte sedimentation rate; IL, interleukin; NSAIDs, 
non-steroidal anti-infl ammatory drugs; RA, rheumatoid arthritis; RF, rheumatoid factor; 
SJC, swollen joint count; TJC, tender joint count; TNF, tumour necrosis factor. 
 Table 3 Association of baseline IL-22 serum levels with erosive 
disease 
 
 ‘IL-22 normal’ 
(n=25) * 
 ‘IL-22 high’ 
(n=24) †  p Value ‡ 
Erosive disease at baseline 1/25 (4) 8/24 (33) 0.05
Erosive disease after 1 year 1/24 § (4) 13/23 § (57) <0.01
Erosive disease after 2 years 1/24 § (4) 14/23 § (61) <0.005
 Results are shown as number (%). 
 * Patients with RA characterised by a normal IL-22 serum level (<7.5 pg/ml). 
 † Patients with RA characterised by a raised IL-22 serum level (>7.5 pg/ml). 
 ‡ Multivariate regression analysis was performed to control for confounding effects of 
anti-CCP-and RF positivity, baseline CRP and DAS28. 
 § One patient from each group was lost during follow-up. 
 anti-CCP, anti-cyclic citrullinated peptides; CRP, C-reactive protein; DAS28, 
Disease Activity Score in 28 joints; IL-22, interleukin 22; RA, rheumatoid arthritis; 
RF, rheumatoid factor. 
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in patients with RA and in controls, it was specifi cally enriched 
in Th1 cells of patients with RA ( fi gure 2C ). Together, the data 
reveal an enhanced IL-22 expression by RA CD4 T cells. However, 
the increase of IL-22-producing Th17 cells in patients with RA 
is probably due to the general increase of Th17 cells as reported 
previously by us 13 —for example, both IL-22-producing and non-
producing Th17 cells, while within Th1 cells, IL-22-producing cells 
were specifi cally enriched. 
 DISCUSSION 
 IL-22 has been recently suggested to be involved in joint 
 pathology in autoimmune arthritis. Here, we have analysed 
IL-22 in patients with early, untreated RA. IL-22 serum levels 
were elevated in about 50% of the patients. Of potential impli-
cation for clinical rheumatology, elevated serum IL-22 at baseline 
was signifi cantly associated with the development of bone ero-
sions early in the course of the disease and might, thus, provide 
a novel means for predicting aggressive disease. As a potential 
source of elevated IL-22 levels in RA, increased frequencies of 
IL-22-producing CD4 T cells could be detected. 
 Whereas a murine study of autoimmune arthritis has pointed 
towards a role for IL-22 in arthritic joint destruction, 2 the knowl-
edge about IL-22 in human autoimmune arthritis is limited. In 
RA, IL-22 mRNA was detected in synovial tissue directly as well 
as in synovial fl uid mononuclear cells. 3 The presence of increased 
Th17 cell-associated cytokines including IL-22, particularly in 
the synovium of patients with early RA, further supports the 
idea that IL-22 might play a role in RA pathophysio logy. 4 With 
regard to the source of IL-22, IL-22 expression was observed in 
CD4 T cells infi ltrating the infl amed synovial tissue in patients 
with juvenile idiopathic arthritis. 14 Increased numbers of IL-22-
positive CD4 T cells in the peripheral circulation of patients 
with RA have been reported. 15  16 However, in those studies 
the authors did not investigate in detail the source of IL-22-
producing cells within the CD4 T cell subsets—for example, 
Th1, Th17, or Th22. Based on our fi ndings, elevated IL-22 pro-
duction appears to be a general feature of infl ammatory CD4 T 
cells in RA that is embedded in every CD4 T effector cell subset. 
This observation of elevated IL-22 production irrespective of a 
particular CD4 T cell subset emphasises the altered phenotype 
of CD4 T cells in RA and is in line with fi ndings associating CD4 
T cells with the disease development. 17 
 An indication for the pathophysiological role of IL-22 in 
autoimmune diseases was initially provided by the analysis of 
patients with psoriasis. In those patients, elevated IL-22 serum 
levels correlated with disease severity. 18 Data from a murine 
model of psoriasis-like autoimmune disease further support a 
pathogenic role of this cytokine in psoriasis as neutralisation of 
IL-22 prevented the development of skin manifestations. 19 An 
association between IL-22 levels and disease activity has also 
been reported in patients with Crohn’s disease. 20 In our study, 
we show for the fi rst time an association between IL-22 and 
disease outcome in RA, implicating a potential pathophysi-
ological role of this cytokine also in the course of RA. The 
 Figure 2  High interleukin 22 (IL-22) levels associated with synovitis in early rheumatoid arthritis (RA) derive from different CD4 T cell 
subpopulations. (A) Representative fl ow cytometry dot plots for expression of IL-22 and IL-17 (upper panels), and IL-22 and IFNγ (lower panels). 
Values indicate the cell frequencies in the respective quadrants. (B) Frequencies of IL-22-producing cells within CD4 T cells after 5 days of expansion, 
followed by stimulation with phorbol myristate acetate and ionomycin, and intracellular cytokine staining for IL-22, IL-17 and IFNγ. Box-and-whisker 
plots show the median, IQR, and 95% CI of fi ve healthy controls (HC) and four patients with RA. (C) Ratios of IL-22-producing to IL-22-non-producing 
cells within Th17 cells (left panel) and Th1 cells (right panel). Bars show the mean + SEM of fi ve HC and four patients with RA. IFNγ, interferon γ. 
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mechanisms by which IL-22 contributes to RA pathogenesis are 
not  completely clear. IL-22 has no direct effects on immune cells. 
It targets fi broblasts and osteoclasts and might thereby mediate 
structural joint changes. The overall proinfl ammatory effect of 
IL-22 in arthritis seems, therefore, to be rather mild. 21 This is in 
line with our observation, that patients with high and normal 
IL-22 serum levels did not differ in their clinical infl ammatory 
parameters, such as disease activity, but did display a signifi cant 
difference in erosive joint changes ( table 3 ). Consistent with this, 
IL-22 knockout mice demonstrated reduced bone destruction in 
collagen-induced arthritis but their disease activity did not differ 
from that of their wild-type littermates. 2 
 A recent study has demonstrated elevated expression of IL-22 
in the bronchial mucosa of healthy smokers compared with 
healthy non-smokers, suggesting a link between smoking and 
increased expression of IL-22. 22 Although the proportion of 
autoantibody-positive (RF, anti-CCP) patients as well as smok-
ers was greater in the ‘IL-22 high’ group compared with the ‘IL-
22 normal’ RA group, this difference was not signifi cant. When 
we stratifi ed the patients with high levels of IL-22 into smokers 
and non-smokers (to exclude the possibility that the difference 
in IL-22 expression between the two cohorts was biased owing 
to smoking), no signifi cant difference in IL-22 serum levels was 
found. Even more importantly, the addition of the variable 
‘smoking habit’ into the multivariate regression analysis did not 
change the signifi cant and independent association between 
IL-22 baseline levels and erosive disease. 
 Manifestation and long-term course of RA are characterised 
by a considerable heterogeneity making it diffi cult to establish 
optimal treatment strategies. Although a number of studies have 
demonstrated the prognostic value of demographic, clinical, labo-
ratory and genetic characteristics for the development of erosive 
RA, some of the results are confl icting, which indicates the need 
for further predictive factors. 23 Further biomarkers refl ecting the 
outcome for joint damage would be clinically helpful to iden-
tify patients with a potentially aggressive disease course. The 
association of elevated IL-22 serum levels with bone erosions 
in patients with RA early in their disease suggests the poten-
tial of this cytokine as a predictive marker early in the course 
of the disease. Of the analysed patients, 24/49 demonstrated 
increased IL-22 serum levels very early in the disease (average 
disease duration of 4 months). Of those 24 patients, 33% had 
developed erosions of hands and feet already at their fi rst visit to 
a rheumatologist. In contrast, only 4% of the patients with IL-22 
serum levels within the normal range had developed erosions at 
baseline. In the course of the disease, elevated serum IL-22 at 
baseline became even more prognostic as in the group of ‘IL-22 
high’ patients nearly two out of three patients had developed 
erosions after 2 years, in contrast to only one out of 24 ‘IL-22 
normal’ patients despite comparable treatment regimens. Thus, 
IL-22 might be useful as a serological marker for early predic-
tions of joint erosions and might contribute to treatment stratifi -
cation in patients with early RA. The data provide novel insight 
into the pathophysiology of RA, suggesting a possible role of 
IL-22 in arthritic joint destruction and defi ning a potential for 
this cytokine as a predictive marker of destructive disease. 
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